Market Trends for Cell Therapies

Newer technologies for treating severe diseases are making their way into medical care, with major new possibilities for doctors and patients, especially where there is significant medical need. Examples of these new technologies are advanced therapy medicinal products (ATMP), which over the long term will change how we view medical care and which diseases are curable. The advantages over traditional drug therapies are numerous. Where traditional drugs often only slow the course of a disease, or continually compensate for deficiencies in the body’s biological and chemical processes through lifelong treatments, cell and gene therapies have the potential to correct whatever has gone wrong once and for all.

The goal of Idogen’s cell therapy is to become that exact kind of corrective treatment. Cell therapies are a recent addition to treatments for severe diseases and to date only a handful of products have already made it all the way to commercial products. In 2017, Novartis received approval from the US Food and Drug Administration for its Kymriah® CAR-T cell therapy against cancer. The following year, Novartis also received approval in Europe. The approval is regarded as an historic milestone in the establishment of cell therapies, reducing uncertainty among those investors who were previously doubtful about this area. Leading regulatory agencies currently predict that a large number of cell and gene therapy treatments will be registered over the next few years.

In recent years, a number of smaller cell therapy companies have signed commercial license agreements with global pharmaceutical companies under attractive terms. The acquisition of TxCell by Sangamo Therapeutics is one example. The company has developed a CAR-treg platform, which uses cell therapy to provide a local immunosuppressive effect for the treatment not only of conditions including organ rejection in conjunction with transplantation but also Crohn’s disease and multiple sclerosis. TxCell was still in the preclinical stage at the time of acquisition, and the purchase price totalled MUSD 84. [1]

Leading regulatory agencies currently predict that a large number of cell and gene therapy treatments will be registered over the next few years.

Cell therapy – from early phase to clinical use

Where cell and gene therapy was once a treatment used extremely selectively for a few diseases around the world, there are now products commercially available for severely ill patients with great medical need (Reference : Regional Personnel (2019) ”Where are the Biggest Talent Gaps in Cell and Gene Therapy.” Available at: https://regionalpersonnel.com/where-are-the-biggest-talent-gaps-in-cell-and-gene-therapy)

  1. https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-completion-txcell-acquisition.